Your browser is no longer supported. Please, upgrade your browser.
Settings
LJPC [NASD]
La Jolla Pharmaceutical Company
Index- P/E- EPS (ttm)-1.44 Insider Own1.47% Shs Outstand27.38M Perf Week0.73%
Market Cap116.38M Forward P/E14.00 EPS next Y0.29 Insider Trans0.00% Shs Float26.98M Perf Month-18.86%
Income-39.40M PEG- EPS next Q0.56 Inst Own77.40% Short Float11.10% Perf Quarter-24.64%
Sales33.40M P/S3.48 EPS this Y66.40% Inst Trans-0.08% Short Ratio8.83 Perf Half Y2.74%
Book/sh-3.36 P/B- EPS next Y-40.40% ROA-41.70% Target Price- Perf Year-37.42%
Cash/sh- P/C- EPS next 5Y13.20% ROE48.40% 52W Range3.36 - 8.10 Perf YTD6.44%
Dividend- P/FCF- EPS past 5Y11.60% ROI39.00% 52W High-49.01% Beta2.35
Dividend %- Quick Ratio2.50 Sales past 5Y99.50% Gross Margin76.60% 52W Low23.03% ATR0.28
Employees59 Current Ratio3.00 Sales Q/Q50.70% Oper. Margin- RSI (14)42.75 Volatility5.41% 6.13%
OptionableYes Debt/Eq- EPS Q/Q86.30% Profit Margin- Rel Volume0.49 Prev Close3.85
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume339.08K Price4.13
Recom2.50 SMA20-1.94% SMA50-19.35% SMA200-10.12% Volume165,310 Change7.27%
Nov-26-19Downgrade H.C. Wainwright Buy → Neutral
Nov-25-19Downgrade SunTrust Buy → Hold
Jan-23-19Upgrade JP Morgan Underweight → Neutral
Jan-14-19Upgrade Jefferies Underperform → Hold
Feb-12-18Downgrade Jefferies Buy → Underperform
Jan-25-18Reiterated Chardan Capital Markets Neutral $90 → $100
Dec-26-17Reiterated SunTrust Buy $57 → $65
Dec-22-17Reiterated SunTrust Buy $67 → $65
Dec-22-17Reiterated H.C. Wainwright Buy $62 → $91
Dec-21-17Initiated H.C. Wainwright Buy $62
Dec-08-17Downgrade JP Morgan Overweight → Underweight
Aug-30-17Initiated JP Morgan Overweight $36
Feb-27-17Reiterated SunTrust Buy $38 → $57
Jun-22-16Initiated SunTrust Buy $30
May-24-16Initiated Lake Street Buy $25
Sep-08-15Reiterated Chardan Capital Markets Buy $60 → $80
Jul-07-15Reiterated Chardan Capital Markets Buy $54 → $60
May-11-15Reiterated H.C. Wainwright Buy $29 → $20
Apr-21-15Initiated Oppenheimer Outperform $43
Mar-20-15Reiterated H.C. Wainwright Buy $20 → $29
Mar-11-21 03:12AM  
Mar-08-21 10:45AM  
08:55AM  
Jan-16-21 01:41AM  
Jan-12-21 08:15AM  
07:00AM  
Dec-28-20 03:08AM  
Dec-23-20 08:56AM  
Dec-02-20 10:15PM  
Nov-13-20 07:07AM  
Nov-09-20 05:35PM  
Oct-19-20 03:30PM  
Oct-09-20 10:49AM  
Aug-25-20 08:31AM  
Aug-21-20 02:02PM  
Aug-06-20 08:30AM  
Jul-28-20 04:16PM  
04:15PM  
Jun-24-20 07:30AM  
Jun-22-20 12:14PM  
Jun-14-20 07:00AM  
Jun-10-20 04:22PM  
May-21-20 08:30AM  
May-07-20 12:55PM  
May-06-20 08:41AM  
May-04-20 09:55AM  
08:30AM  
Apr-27-20 12:31PM  
Apr-13-20 08:30AM  
Apr-07-20 08:30AM  
Apr-06-20 08:30AM  
Apr-03-20 08:30AM  
Apr-02-20 08:30AM  
Mar-13-20 08:00AM  
Mar-02-20 09:55AM  
08:30AM  
Feb-24-20 12:30PM  
Jan-27-20 08:23AM  
Jan-18-20 05:09PM  
Jan-15-20 07:00AM  
Jan-09-20 08:00AM  
Dec-13-19 03:07PM  
Nov-26-19 08:06AM  
Nov-25-19 09:04AM  
08:35AM  
08:30AM  
Nov-15-19 09:52AM  
Nov-12-19 06:35PM  
04:47PM  
12:21PM  
Nov-11-19 09:59AM  
Oct-16-19 10:32AM  
Aug-29-19 09:00AM  
Aug-16-19 02:38PM  
Aug-14-19 03:36PM  
Aug-01-19 09:35AM  
08:00AM  
Jul-30-19 11:53AM  
11:31AM  
Jul-23-19 09:00AM  
Jul-01-19 08:39AM  
Jun-28-19 06:30AM  
Jun-11-19 11:55AM  
Jun-07-19 02:02PM  
Jun-06-19 09:00AM  
May-22-19 01:49PM  
May-06-19 06:25PM  
05:15PM  
04:11PM  
May-02-19 10:33AM  
Apr-29-19 01:25PM  
Apr-24-19 09:00AM  
Mar-11-19 07:30AM  
Mar-08-19 02:49PM  
Mar-07-19 04:01PM  
01:05PM  
Mar-06-19 08:56AM  
Mar-05-19 07:24AM  
Mar-04-19 06:33PM  
04:01PM  
Feb-25-19 04:04PM  
Feb-14-19 07:18PM  
Feb-05-19 08:20AM  
Jan-18-19 07:00AM  
Jan-10-19 07:00AM  
Jan-09-19 11:28AM  
Jan-07-19 10:25PM  
02:36PM  
12:55PM  
09:00AM  
Jan-04-19 09:00AM  
Dec-22-18 01:38AM  
Nov-06-18 08:35AM  
Oct-31-18 12:04PM  
Oct-25-18 03:55PM  
Oct-24-18 06:10PM  
05:06PM  
04:01PM  
07:48AM  
Oct-18-18 04:01PM  
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TANG KEVIN CDirectorSep 09Buy4.03126,665509,9409,405,490Sep 09 06:55 PM
RAMSAY DAVID ADirectorSep 08Buy3.831,0003,83048,000Sep 10 04:02 PM
TANG KEVIN CDirectorSep 08Buy3.9084,152328,5299,278,825Sep 09 06:55 PM
TANG KEVIN CDirectorSep 04Buy3.8267,552258,3599,194,673Sep 09 06:55 PM
RAMSAY DAVID ADirectorAug 24Buy3.767,00026,28847,000Aug 24 04:22 PM
RAMSAY DAVID ADirectorAug 21Buy3.9728,000111,10840,000Aug 24 04:22 PM
RAMSAY DAVID ADirectorAug 20Buy4.1712,00050,06012,000Aug 24 04:22 PM
TANG KEVIN CDirectorAug 14Buy3.88168,669653,6949,127,121Aug 14 04:49 PM
TANG KEVIN CDirectorAug 13Buy3.65219,465800,5868,958,452Aug 14 04:49 PM
TANG KEVIN CDirectorAug 12Buy3.4743,513150,8208,738,987Aug 14 04:49 PM
TANG KEVIN CDirectorJun 04Buy4.94215,8121,065,6368,695,474Jun 04 06:26 PM
TANG KEVIN CDirectorJun 03Buy4.90145,764714,7838,479,662Jun 04 06:26 PM
TANG KEVIN CDirectorJun 02Buy4.88253,5531,237,0608,333,898Jun 04 06:26 PM